加载中
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.
收盘时
US$112.08
−US$0.32 · -0.28%
盘后
US$112.08
US$0.00 · 0.00%
10月12日 19:30 ET
盘中时间采用ET。市场数据可能有所延迟。
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.
日内区间
当前US$112.08
52周区间
当前US$112.08
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
27
偏贵
情绪
44
多空交织
风险
51
风险偏高
动量
71
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.
日内区间
当前US$112.08
52周区间
当前US$112.08
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 3920万 USD | 4707.2万 USD | 7859.2万 USD | 4682.6万 USD | 7283.2万 USD |
| 毛利 | 3920万 USD | 4707.2万 USD | 7859.2万 USD | 4682.6万 USD | 7283.2万 USD |
| 研究与开发 | 3.17亿 USD | 2.4亿 USD | 1.89亿 USD | 1.64亿 USD | 1.37亿 USD |
| 销售、一般及管理费用 | 6820万 USD | 6353.4万 USD | 5504.1万 USD | 4383.4万 USD | 3634.5万 USD |
| 营业费用 | 3.89亿 USD | 3.09亿 USD | 2.44亿 USD | 2.08亿 USD | 1.73亿 USD |
| 利息收入 | 3802.6万 USD | 3802.6万 USD | 1876.4万 USD | 662.4万 USD | 48.8万 USD |
| 利息支出 | 24.9万 USD | 24.9万 USD | 19.6万 USD | 17.6万 USD | 17.5万 USD |
| 折旧和摊销 | 831.3万 USD | 737.3万 USD | 356.5万 USD | 297.7万 USD | 239.7万 USD |
| 营业利润 | −3.49亿 USD | −2.62亿 USD | −1.66亿 USD | −1.61亿 USD | −1.01亿 USD |
| 净利润 | −3.11亿 USD | −2.24亿 USD | −1.47亿 USD | −1.55亿 USD | −1亿 USD |
公司数据更新于 2026年10月12日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$138.2
上涨空间 23.30%价格历史记录不可用
最高：US$180平均的：US$138.2最低：US$97.00报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI2.49亿0.01%2.3万亿 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM1.84亿0.24%787.4亿 USD0.19%US$277.9-0.37%
Vanguard Morningstar Small-Cap ETFVB1.8亿0.10%1853亿 USD0.03%US$288.16-0.46%
State Street SPDR S&P Biotech ETFXBI1.18亿1.20%98.74亿 USD0.35%US$151.4-1.54%
Vanguard Morningstar Small-Cap Growth ETFVBK1.03亿0.23%447亿 USD0.05%US$340.88-1.12%
Vanguard Extended Market ETFVXF8745.7万0.09%954亿 USD0.05%US$233.52-0.63%
iShares Biotechnology ETFIBB6516.41万0.60%108.2亿 USD0.44%US$204.26-1.08%
iShares Russell 2000 Growth ETFIWO5372.6万0.39%139.17亿 USD0.24%US$353.71-0.86%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap ETFVBState Street SPDR S&P Biotech ETFXBIVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBiShares Russell 2000 Growth ETFIWOAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
